Today: 20 March 2026
Caterpillar stock jumps 7% as Dow tops 50,000 — what to watch before Monday
7 February 2026
2 mins read

Caterpillar stock jumps 7% as Dow tops 50,000 — what to watch before Monday

New York, Feb 7, 2026, 14:14 EST — Market shut its doors for the day

  • Caterpillar surged 7.1% on Friday, closing at $726.20—marking one of its sharpest single-day jumps this year.
  • The Dow surged past 50,000 for the first time ever, marking its biggest boost to date as the index closed above that milestone.
  • Focus shifts to delayed U.S. jobs numbers and next week’s inflation figures, as traders look for clues on rates.

Caterpillar Inc. surged 7.1% to finish Friday at $726.20, pushing the heavy-equipment giant further into the ranks of the Dow’s top single-stock movers.

This shift landed just as investors were tilting back toward stocks tied to the economy, following a stretch of nervousness over AI and software plays. “What’s driven it recently has been the broadening that we have seen in the market,” said Chuck Carlson, chief executive officer at Horizon Investment Services. https://www.reuters.com/business/dow-jones…

Caterpillar looms large in the Dow, thanks to the index’s price-weighted setup—higher share prices pack extra punch, no matter the company’s market cap. When CAT makes a sharp move, the impact on the index is immediate.

Caterpillar is showing up in investor chatter as a kind of test: will the market put money back into “real economy” names — construction, mining, engines — as AI-driven power consumption starts to shape capital spending?

Caterpillar shares have climbed roughly 27% year to date as of Friday’s close, following a surge of over 50% in 2025. That kind of move is drawing in short-term traders, not just the usual long-term investors who see CAT as a global-growth proxy.

A robust close to 2025 has buoyed the fundamentals story. On Jan. 29, the company reported record full-year sales and revenues of $67.6 billion, along with a record backlog—orders locked in but not delivered yet. CEO Joe Creed described entering the new year with “strong momentum.” Still, the release noted margin pressure, citing higher costs as one factor. https://investors.caterpillar.com/news/new…

Caterpillar’s spike had company. Deere tacked on nearly 3% Friday, while United Rentals jumped close to 6%—a clear sign of buyers rotating into cyclicals as the market bounced back. https://tradingeconomics.com/de%3Aus https://www.investing.com/equities/united-…

U.S. markets will be closed Saturday, putting the spotlight on whether rate dynamics play along. S&P Global Market Intelligence flagged that next week’s postponed U.S. jobs and inflation prints could “fuel Fed policy expectations.” https://www.spglobal.com/marketintelligenc…

Next up: inflation. The Bureau of Labor Statistics is set to release January’s CPI numbers Friday, Feb. 13, with the report dropping at 8:30 a.m. ET. https://www.bls.gov/schedule/news_release/…

For those eyeing dividend payouts, Caterpillar’s latest quarterly dividend hits accounts on Feb. 19, with the ex-dividend date having landed Jan. 20. https://investors.caterpillar.com/stock-in…

The risk here is clear enough. If inflation comes in hotter, yields spike, or concerns resurface about tariffs and manufacturing expenses, industrials trading above the market could lose altitude fast — especially those that have surged past the pack.

Monday’s open will test if Caterpillar can hang onto Friday’s advance. Investors also face a choice: stick with cyclicals or not, as they wait for the postponed U.S. jobs report due Wednesday, Feb. 11, and CPI numbers coming Friday, Feb. 13.

Stock Market Today

  • Kessler Topaz Meltzer & Check Files Securities Fraud Class Action Against Soleno Therapeutics
    March 20, 2026, 1:23 PM EDT. Kessler Topaz Meltzer & Check, LLP has filed a securities fraud class action lawsuit against Soleno Therapeutics, Inc. (NASDAQ: SLNO) concerning purchases of SLNO stock between March 26 and November 4, 2025. The lawsuit alleges that Soleno made materially false statements and omissions about safety concerns in its Phase 3 clinical trial for diazoxide choline extended-release tablets used to treat hyperphagia linked to Prader-Willi syndrome. The firm claims the company concealed issues relating to excess fluid retention in trial participants. Investors have until May 5, 2026, to seek lead plaintiff status. The complaint is pending in the U.S. District Court for the Northern District of California under case number 3:26-cv-01979. Investors who suffered losses are urged to contact the law firm for legal options at no cost.
Roche stock price slips into the weekend — here’s what could move shares on Monday
Previous Story

Roche stock price slips into the weekend — here’s what could move shares on Monday

ICBC stock: Weekend gold caps and China CPI loom after A-shares end at 7.26 yuan
Next Story

ICBC stock: Weekend gold caps and China CPI loom after A-shares end at 7.26 yuan

Go toTop